Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CSLCSLLY -0.83%67 3-Year Revenue Growth Rate is 4.60% as of Jun. 2026, which is 68% below its 10-year median of 14.40. GuruFocus rates CSLLY with a GF Score™ of 67/100 and a GF Value™ of $48.31 (Significantly Undervalued). The stock has 6 warning signs investors should review. Among 768 Biotechnology companies, CSL ranks better than 52.21% on this metric.
During the past 12 months, CSL's average Revenue per Share Growth Rate was -4.90% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 4.60% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 11.00% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 11.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.
During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of CSL was 23.90% per year. The lowest was 3.90% per year. And the median was 14.40% per year.
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.
CSL 3-Year Revenue Growth Rate Related Terms
CSLLY vs VRTX, REGN, MRNA: 3-Year Revenue Growth Rate Comparison
For the Biotechnology subindustry, CSL's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CSL 3-Year Revenue Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CSL's 3-Year Revenue Growth Rate distribution charts can be found below:
* The bar in red indicates where CSL's 3-Year Revenue Growth Rate falls into.
This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.
What does a 3-Year Revenue Growth Rate of 4.60% mean?
CSL (CSLLY) has a 3-Year Revenue Growth Rate of 4.60% as of Jun. 2026. 3-Year Revenue Growth Rate is the 3-year average growth rate of Revenue per share. View historical data for CSL and its competitors. This is 68% below median its historical median of 14.40. Over the past decade, CSL's 3-Year Revenue Growth Rate has ranged from 3.90 to 23.90. According to the industry distribution chart, CSL ranks #367 out of 768 companies in the Biotechnology industry, placing it in the top 47.8%.
Is CSL's 3-Year Revenue Growth Rate too high?
CSL's current 3-Year Revenue Growth Rate of 4.60% is 68% below median its 10-year median of 14.40. Over the past 10 years, this metric has ranged from a low of 3.90 to a high of 23.90. The Biotechnology industry median 3-Year Revenue Growth Rate is 3.35. CSL's value of 4.60% is 37.3% above this industry median. Based on the distribution chart, CSL ranks #367 out of 768 companies in the Biotechnology industry, which is above the industry midpoint. Overall, CSL has a GF Score™ of 67/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CSL's 3-Year Revenue Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CSL ranks #367 out of 768 companies for 3-Year Revenue Growth Rate. This puts CSL in the upper half of its industry. The industry median 3-Year Revenue Growth Rate is 3.35. CSL's value of 4.60% is 37.3% above this benchmark. Historically, CSL's own 3-Year Revenue Growth Rate has ranged from 3.90 to 23.90 over the past decade. While the company's 10-year median is 14.40 vs. the industry median of 3.35, CSL has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Revenue Growth Rate for a Biotechnology company?
The median 3-Year Revenue Growth Rate among Biotechnology companies is 3.35, based on 768 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Revenue Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Revenue Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CSL's current 3-Year Revenue Growth Rate of 4.60% is 37.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Revenue Growth Rate mean?
A high 3-Year Revenue Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Revenue Growth Rate is the 3-year average growth rate of Revenue per share. View historical data for CSL and its competitors. For the Biotechnology industry, the median 3-Year Revenue Growth Rate is 3.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CSL's current 3-Year Revenue Growth Rate is 4.60%, which is 68% below median its own 10-year median of 14.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CSL stock overvalued right now?
Based on GuruFocus' analysis, CSL (CSLLY) is currently considered Significantly Undervalued. The stock's GF Value™ is $48.31, compared to a current price of $29.91 — trading 38.1% below its estimated fair value. The current 3-Year Revenue Growth Rate is 4.60%, which is 68% below median its 10-year median of 14.40 and 37.3% above the Biotechnology industry median of 3.35. CSL's overall GF Score™ is 67/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Revenue Growth Rate calculated?
3-Year Revenue Growth Rate is calculated from a company's financial statements. For CSL (CSLLY), the current 3-Year Revenue Growth Rate is 4.60% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CSL (CSLLY) Overvalued in 2026?
Based on GuruFocus' analysis, CSL stock appears to be undervalued.
The current stock price of $29.91 is trading 38.1% below its estimated GF Value™ of $48.31.
GuruFocus considers CSL to be Significantly Undervalued.
Key valuation signals for CSLLY:
3-Year Revenue Growth Rate: 4.60% (68% below median its 10-year median of 14.40)
GF Value™: $48.31 vs. price of $29.91 (38.1% below fair value)
Industry Position: 37.3% above the Biotechnology median (#367 of 768)
No single metric tells the full story. See the CSLLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world's second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
67GF Score
Get the complete analysis for CSLLY
3-Year Revenue Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSLLY has been successfully added to your 
